The relationship between CEA, CA125 and NSE and the pathological characteristics of patients with NSCLC and the value of combined detection

doi:10.3969/j.issn.1004-583X.2022.11.005

Abstract

Abstract:

Objective To analyze the relationship between carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), neuron-specific enolase (NSE) and the pathological characteristics of patients with non-small cell lung cancer (NSCLC) and the value of combined detection. Methods Totally 175 NSCLC patients (NSCLC group) who were treated in Shanghai Jinshan District Hospital of Integrated Traditional Chinese and Western Medicine (January 2018-January 2022), and 180 patients with benign pulmonary diseases during the same period (no-NSCLC group) were retrospectively enrolled. The clinical data, the level of CEA, CA125, and NSE of patients at different stages were included as comparators. Spearman correlation analysis was conducted to assess the association between serum indexes and staging system. the diagnostic value of CEA, CA125 and NSE of NSCLC patients, alone and in combination, were analyzed by the receiver operating characteristic (ROC) curve.Results The serum levels of CEA, CA125 and NSE in NSCLC group were markedly higher than those in no-NSCLC group ( $P$ <0.05). The significant increasing trend for serum levels of CEA, CA125 and NSE were found in patients with classification grades Ⅰ-Ⅲ( $P$ <0.05). The results of Spearman correlation analysis showed that CEA, CA125, NSE were positively correlated with the clinical stage of patients with NSCLC ( $r$ =0.579, 0.437, 0.686, $P$ <0.05). The ROC curve was drawn with NSCLC as positive and benign lung disease as negative, the area under the curve (AUC) of CEA, CA125, and NSE for predicting NSCLC, alone and in combination, were 0.809, 0.842, 0.867, and 0.910, respectively ( $P$ <0.05). Conclusion The increased expressions of CEA, CA125 and NSE are detected in NSCLC patients, and increasing trend with the disease progression, the detection of serum levels of CEA, CA125 and NSE alone and in combination had certain diagnostic value for NSCLC.

Key words: carcinoma, non-small-cell lung, carcinoembryonic antigen, carbohydrate antigen 125, neuron-specific enolase, pathological features, diagnostic value

CLC Number:

R730.26

Jia Chengbang, Shen Lijuan, Sun Zhigang. The relationship between CEA, CA125 and NSE and the pathological characteristics of patients with NSCLC and the value of combined detection[J]. Clinical Focus, 2022, 37(11): 992-995.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.11.005

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I11/992

Figures/Tables 5

组别	例数	CEA (μg/L)	CA125 (U/mL)	NSE (ng/mL)
NSCLC组	175	5.33±1.13	42.57±10.62	20.38±5.10
非NSCLC组	180	3.48±1.41	25.95±7.40	13.71±3.12
$t$ 值		13.618	29.609	14.933
$P$ 值		0.000	0.000	0.000

组别	例数	CEA (μg/L)	CA125 (U/mL)	NSE (ng/mL)
NSCLC组	175	5.33±1.13	42.57±10.62	20.38±5.10
非NSCLC组	180	3.48±1.41	25.95±7.40	13.71±3.12
$t$ 值		13.618	29.609	14.933
$P$ 值		0.000	0.000	0.000

组别	例数	CEA(μg/L)	CA125(U/mL)	NSE(ng/mL)
Ⅰ期	27	3.91±1.05	28.76±4.48	9.36±1.15
Ⅱ期	37	4.59±0.68^*	33.80±3.37^*	12.25±1.17^*
Ⅲ期	44	5.52±0.79^*#	40.43±2.54^*#	14.92±1.18^*#
Ⅳ期	67	6.19±0.58^*#&	54.38±3.55^*#&	17.22±1.16^*#&
$F$ 值		76.027	490.164	343.818
$P$ 值		0.000	0.000	0.000

组别	例数	CEA(μg/L)	CA125(U/mL)	NSE(ng/mL)
Ⅰ期	27	3.91±1.05	28.76±4.48	9.36±1.15
Ⅱ期	37	4.59±0.68^*	33.80±3.37^*	12.25±1.17^*
Ⅲ期	44	5.52±0.79^*#	40.43±2.54^*#	14.92±1.18^*#
Ⅳ期	67	6.19±0.58^*#&	54.38±3.55^*#&	17.22±1.16^*#&
$F$ 值		76.027	490.164	343.818
$P$ 值		0.000	0.000	0.000

指标	NSCLC患者临床分期
指标	$r$ 值	$P$ 值
CEA	0.579	0.012
CA125	0.437	0.023
NSE	0.686	0.004

指标	NSCLC患者临床分期
指标	$r$ 值	$P$ 值
CEA	0.579	0.012
CA125	0.437	0.023
NSE	0.686	0.004

指标	AUC值	标准误差	渐进95%置信区间	灵敏度(%)	特异度(%)	诊断阈值
CEA	0.809	0.023	0.764~0.848	70.86	76.54	>4.62
CA125	0.842	0.023	0.799~0.878	69.71	94.97	>32.30
NSE	0.867	0.022	0.827~0.900	72.00	98.32	>11.64
联合检测	0.910	0.015	0.876~0.938	90.86	77.09

指标	AUC值	标准误差	渐进95%置信区间	灵敏度(%)	特异度(%)	诊断阈值
CEA	0.809	0.023	0.764~0.848	70.86	76.54	>4.62
CA125	0.842	0.023	0.799~0.878	69.71	94.97	>32.30
NSE	0.867	0.022	0.827~0.900	72.00	98.32	>11.64
联合检测	0.910	0.015	0.876~0.938	90.86	77.09

References 21

[1]	姜桔红, 李玉勤, 顾莹莹. 晚期非小细胞肺癌免疫检查点抑制剂相关性肌炎的临床病理学特征[J]. 中华结核和呼吸杂志, 2022, 45(1): 47-52.
[2]	董雯婷, 陈娴, 范艳妮, 等. 2005年-2015年非小细胞肺癌住院病例特征分析及趋势预测[J]. 中国病案, 2018, 19(5): 44-47.
[3]	van Delft FA, Schuurbiers M, Muller M, et al. Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer[J]. Heliyon, 2022, 8(10): 10932-10932.
[4]	Li Z, Zhao J. Clinical efficacy and safety of crizotinib and alectinib in alk-positive non-small cell lung cancer treatment and predictive value of CEA and CA125 for treatment efficacy[J]. Am J Transl Res, 2021, 13(11): 13108-13116. pmid: 34956530
[5]	Edge SB, Compton CC. The american joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of tnm[J]. Ann Surg Oncol, 2010, 17(6): 1471-1474. doi: 10.1245/s10434-010-0985-4 pmid: 20180029
[6]	王思斯, 陈明, 孙哲, 等. 非小细胞肺癌生存预测列线图的构建与验证[J]. 实用肿瘤杂志, 2020, 35(4): 327-335.
[7]	周际昌. 实用肿瘤内科学[M]. 北京: 人民卫生出版社, 2003: 202-203.
[8]	王辰, 王建安. 内科学(第3版)[M]. 北京: 人民卫生出版社, 2015: 115-246.
[9]	孔彦, 田亮. 非小细胞肺癌患者血清DJ-1、sMICA水平与临床病理特征及预后的关系研究[J]. 中国现代医学杂志, 2022, 32(5): 64-69.
[10]	田平, 宣小山, 陈敬. CA15-3、CEA、CA125和COX-2联合检测在乳腺癌诊断中的价值[J]. 分子诊断与治疗杂志, 2022, 14(6): 1012-1015.
[11]	Li Z, Zhao J. Clinical efficacy and safety of crizotinib and alectinib in alk-positive non-small cell lung cancer treatment and predictive value of CEA and CA125 for treatment efficacy[J]. Am J Transl Res, 2021, 13(11): 13108-13116. pmid: 34956530
[12]	韩梅, 马明杰, 连俊, 等. 血清AFP、CEA、CA199、CA125、HE4联合检测在卵巢癌诊断中的应用价值[J]. 河北医药, 2022, 44(1): 76-78, 82.
[13]	Clevers MR, Kastelijn EA, Peters BJM, et al. Evaluation of serum biomarker CEA and CA125 as immunotherapy response predictors in metastatic non-small cell lung cancer[J]. Anticancer Res, 2021, 41(2): 869-876. doi: 10.21873/anticanres.14839 pmid: 33517292
[14]	许涛, 杨磊, 刘兴田. 血清CA125、SCCA在肺结核与肺癌患者中的表达对比分析[J]. 临床肺科杂志, 2021, 26(5): 738-741.
[15]	张晓玲. 小细胞肺癌患者血清NSE、SCC的表达水平变化及其临床意义[J]. 实用癌症杂志, 2018, 33(5): 739-741.
[16]	高洁, 张伦军, 彭珂, 等. 血清肿瘤标志物CEA、CYFRA21-1、SCCAg、NSE、ProGRP在不同病理分型肺癌诊断中的应用价值[J]. 南方医科大学学报, 2022, 42(6): 886-891.
[17]	Arrieta O, Varela-Santoyo E, Cardona AF, et al. Association of carcinoembryonic antigen reduction with progression-free and overall survival improvement in advanced non-small-cell lung cancer[J]. Clin Lung Cancer, 2021, 22(6): 510-522. doi: 10.1016/j.cllc.2021.03.014 pmid: 33947631
[18]	Kuroda H, Ichinose J, Masago K, et al. Permissible outcomes of lobe-specific lymph node dissection for elevated carcinoembryonic antigen in non-small cell lung cancer[J]. Medicina (Kaunas), 2021, 57(12): 1365-1365.
[19]	漏佳颖, 徐瑞军, 沈丽君, 等. 血清前白蛋白联合CEA、CYFRA 21-1、SCC-Ag检测诊断非小细胞肺癌的应用分析[J]. 浙江临床医学, 2021, 23(12): 1798-1800.
[20]	Dal Bello MG, Filiberti RA, Alama A, et al. The role of CEA, CYFRA21-1 and nse in monitoring tumor response to nivolumab in advanced non-small cell lung cancer (nsclc) patients[J]. J Transl Med, 2019, 17(1): 74-74. doi: 10.1186/s12967-019-1828-0 pmid: 30849967
[21]	Bes-Scartezini F, Saad Junior R. Prognostic assessment of tumor markers in lung carcinomas[J]. Rev Assoc Med Bras (1992), 2022, 68(3): 313-317. doi: 10.1590/1806-9282.20210259 URL